An observational study in Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (NFP), sponsored by University Hospital, Angers. Not yet recruiting. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University Hospital, Angers · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Neurofibromatosis type 1 (NF1) is a multisystemic genetic disorder associated with frequent tumor, skin, visceral, and bone manifestations. Plexiform neurofibromas (PFNs), whether superficial or deep, affect 20 to 50 percent of patients and are responsible for significant morbidity. Inoperable, symptomatic PFNs can now be treated with targeted therapy (selumetinib) in both children and adults. Furthermore, NF1 patients frequently present with bone abnormalities, such as bone dysplasia, scoliosis, or reduced bone mineral density, suggesting impaired mineralization.
Inorganic pyrophosphate (PPi) is a potent antagonist of bone mineralization. It has been shown in a mouse model of NF1 and in human Schwann cell cultures derived from patients with NF1 (2 cases) that there is activation of genes regulating PPi homeostasis, particularly ANKH and ENPP1.
This study aims to measure plasma PPi levels in a cohort of patients with NF1 from the general population, based on their phenotype-specifically, the presence, location, and characteristics of NFPs-as well as their calcium and phosphorus levels.
177 studies on the registry are indexed under Neurofibromatosis 1; 44 are open to participants now.
This study's planned enrollment of 40 is below the median of 176 across 59 observational studies indexed under Neurofibromatosis 1.
Browse Neurofibromatosis 1 studies →University Hospital, Angers is the lead sponsor of 481 studies on the registry; 123 are open to participants now.
Counted across the registry records on this site, refreshed daily.
40 patients. Age ≥18 years ; Confirmed diagnosis of NF1, based on current clinical and/or molecular criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PPi plasma concentration.
Time frame: Visite 1
Plasma PPI Levels in NF1 patients
Time frame: At the time of the consultation
Urine PPI Levels in NF1 patients
Time frame: At the time of the consultation
presence of a plexiform neurofibroma in NF1 patients
Time frame: At the time of the consultation
presence of bone abnormalities in NF1 patients
Time frame: At the time of the consultation
Urinary PPI measurement in newly diagnosed patients with NF1
Time frame: At the time of the consultation
Location of plexiform neurofibromas
Time frame: At the time of the consultation
Calcium measurement
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)
Time frame: At the time of the consultation
Phosporus measurement
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)
Time frame: At the time of the consultation
Vitamine D Assay
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)
Time frame: At the time of the consultation
Parathyroid hormone (PTH) measurement
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)
Time frame: At the time of the consultation
Treatment with selumetinib
Time frame: Visite 1
No study locations are listed for this record.
Start is estimated for Apr 2027; primary completion for Jun 2028, 14 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.